Arialys Therapeutics, Inc.

If you missed the conversation with our President & CEO, Peter Flynn and Josh Schimmer for the Cantor Fitzgerald Private Company Showcase, watch it on-demand here: https://lnkd.in/gZQC33X5 They discussed “A New Neuropsych Paradigm” – how our evolving understanding of autoimmune mechanisms may lead to future therapeutic approaches for neuropsychiatric disease. Peter shared insights on advancing our lead therapeutic candidate, ART5803, in clinical trials and provided an update on what’s next in development. ART5803 is a precision medicine being developed for the treatment of anti-NMDAR encephalitis (ANRE). This first-in-class therapy holds promise for a new standard of care in ANRE, with further potential to treat other anti-NMDAR autoimmune neuropsychiatric conditions, including psychosis and dementia. #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #immunology #drugdiscovery #drugdevelopment #neuropsychopharmacology #autoimmune #psychosis #dementia

Mark your calendar for Wednesday, November 13th, for BioPharma Dive’s virtual event: 𝗕𝗶𝗼𝘁𝗲𝗰𝗵'𝘀 𝗡𝗲𝘄 𝗡𝗼𝗿𝗺𝗮𝗹: 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀. Our President & CEO, Peter Flynn, will join Christiana Bardon M.D., Co-managing Partner at MPM BioImpact, and Andrew Miller, Chairperson at Progentos Therapeutics and founder of Karuna Therapeutics on a panel, moderated by Jacob Bell, to discuss, 𝗡𝗲𝘄 𝗔𝗿𝗲𝗮𝘀 𝗼𝗳 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗠𝗼𝗺𝗲𝗻𝘁𝘂𝗺. See more about the event and register here: https://lnkd.in/dTSM9tzQ #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #immunology #drugdiscovery #drugdevelopment #neuropsychopharmacology #autoimmune #psychosis

On Tuesday, November 12th, our President & CEO, Peter Flynn, will sit down with Josh Schimmer in a virtual fireside chat for the Cantor Fitzgerald Private Company Showcase. Peter and Josh will discuss the emerging field of autoimmune neuropsychiatric disease and how our new understanding of these mechanisms will lead to future therapeutic approaches.  Peter will share more about Arialys Therapeutics achieving an important milestone of advancing our lead therapeutic candidate, ART5803, in clinical trials and what’s ahead in development. ART5803 is a precision medicine being developed for the treatment of anti-NMDAR encephalitis (ANRE). This first-in-class therapy holds promise for a new standard of care in ANRE, with further potential to treat other anti-NMDAR autoimmune neuropsychiatric conditions, including psychosis and dementia. If you’d like to attend, register here: https://lnkd.in/gpjQy62S #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #immunology #drugdiscovery #drugdevelopment #neuropsychopharmacology #autoimmune #psychosis

We are excited to announce the appointment of Sankalp Gokhale MD, MBA, MD, MBA, as our new Chief Medical Officer! Dr. Gokhale is a U.S. board-certified neurologist with over 15 years of experience in clinical practice and pharmaceutical development, bringing a wealth of knowledge to the Arialys team as we advance new precision medicines for autoimmune neuropsychiatric diseases. With deep expertise in running global clinical studies, especially in rare neurological diseases, Dr. Gokhale will play a crucial role as we progress our lead therapeutic candidate, ART5803, in clinical trials. Please join us in welcoming Dr. Gokhale to Arialys Therapeutics! We’re excited advancing new therapeutics to help patients with autoimmune neurological and neuropsychiatric diseases and the difference we can make together. Read the release for more details: https://lnkd.in/gW7MpJAr #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry #autoimmune #psychosis

We are pleased to announce that the first participants have been dosed in a Phase 1 clinical trial of ART5803, a precision medicine for the treatment of autoimmune neuropsychiatric diseases. ART5803 is being developed for the treatment of anti-NMDAR autoimmune neuropsychiatric diseases, including anti-NMDAR encephalitis (ANRE). Read the release for more details: https://lnkd.in/gFYHey7H #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry #autoimmune #psychosis

Our President & CEO, Peter Flynn, will be presenting at the BIO Investor Forum in San Francisco on Wednesday, October 16th at 11:30 AM PT. He will be sharing more about the advancement of our lead therapeutic candidate, ART5803, in clinical trials. ART5803 is a precision medicine being developed for the treatment of anti-NMDAR autoimmune neuropsychiatric diseases, including anti-NMDAR encephalitis (ANRE). See more about #BIF2024 here: https://bif.bio.org/  #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry #autoimmune #psychosis

We are hiring! We are currently building out our team for our upcoming #clinicaltrial to advance our lead drug candidate, ART-5803, a unique precision medicine approach to treat neuropsychiatric disorders driven by autoimmunity.  If you are interested in applying breakthrough science to expand treatment options for patients, please see our #openpositions. ➡️ Senior Clinical Trial Manager or Associate Director, Clinical Operations ➡️ Senior Director Project Management ➡️ Clinical Trial Manager See more here: https://lnkd.in/ecEzZpyw #biotech #SanDiego #careers #openposition #nowhiring

In this PharmaVoice Biotech Spotlight, our CEO Peter Flynn shares more about the vision of the company, why it matters, the terrifying and rapid symptoms of #ANRE and how our lead therapeutic candidate to treat autoimmune psychosis is “elegantly simple.” Read the article here: https://lnkd.in/ebPnT8z3 #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry #autoimmune #pyschosis

We are excited to welcome Peter Flynn, Ph.D., as President and Chief Executive Officer of Arialys Therapeutics, Inc.! Peter has more than 20 years of executive leadership experience in the biotech industry, from private start-ups to established publicly traded companies, scaling companies through key financings and pharma partnerships, advancing novel therapeutics from scientific breakthrough to the clinic, and commercializing FDA-approved medicines. He joins us as we advance our lead drug candidate, ART5803, into clinical study for the treatment of ANRE and autoimmune psychosis. In addition, Jay Lichter, Ph.D., Managing Partner of Avalon BioVentures and former President and CEO of Arialys, has been appointed Chair of the company’s Board of Directors. Read the release here: https://lnkd.in/g44kyQCD #autoimmunedisease #autoimmunity #neurology #neuropsychiatric #neuropsychiatry  #precisionmedicine #antiNMDAR #ANRE #NMDA #encephalitis #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #precisionpsychiatry

Changing minds about autoimmune encephalitis: Drug Discovery News delves into the complex presentation and treatment of anti-NMDA receptor encephalitis (ANRE) and the precision medicine antibody that we hope will provide a meaningful treatment option. Aparna Nathan does a great job describing the rare condition, which causes immune cells to attack a receptor on the surface of neurons, leading to an array of psychiatric symptoms such as headaches, hallucinations, mania, and memory loss. It's also a story about serendipity, cross-disciplinary collaboration between neurologists and immunologists, and the potential of an antibody-specific targeted treatment that might ultimately be applicable to a larger swath of the population. Read more about our mission to 'put out a fire in the brain' and our lead drug candidate ART5803: https://lnkd.in/gy_QTFPP #encephalitis #NMDA #neurology #immunology #drugdiscovery #drugdevelopment #pharma #neuropsychopharmacology #neuropsychiatry #ANRE